ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0139

A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Abstract Number: 0140

Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Abstract Number: 0141

Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
Abstract Number: 0142

A Systemic Autoinflammatory Syndrome Caused by NEMO Exon 5 Skipping
Abstract Number: 0143

National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
Abstract Number: 0144

The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Abstract Number: 0145

Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
Abstract Number: 0146

Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Abstract Number: 0147

Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
Abstract Number: 0148

Dysferlin Associated Autoinflammatory Disease Causing Systemic Inflammation and Sterile Lung Abcesses Through Impaired Efferocytosis
Abstract Number: 0149

Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations
Abstract Number: 0150

Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
Abstract Number: 0151

Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
Abstract Number: 0152

Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
Abstract Number: 0153

Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].